Odyssey Therapeutics (ODTX) Stock Price, News & Analysis

Company Overview

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, structural biology, medicinal chemistry and other drug-discovery technologies to identify therapies designed to target specific disease mechanisms.

Odyssey’s research programs are centered on small-molecule therapeutics intended to modulate immune pathways and address conditions with significant unmet medical needs. Its development activities span immunology and oncology, with programs progressing through preclinical and clinical research as the company evaluates potential treatments for patients in these areas.

Odyssey Therapeutics was founded in 2021 and is based in the United States. Gary Glick, who previously helped establish Nimbus Therapeutics, is the company’s founder and chief executive officer. The company’s work is primarily directed toward advancing internally discovered drug candidates through development and potential commercialization.

Key Stats

• Today's Range: $21.70 to $22.66
• 50-Day Range: $17.67 to $28.76
• 52-Week Range: $15.10 to $29.05
• Volume: 66,311 shs
• Average Volume: 302,672 shs
• Market Capitalization: $1.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.75
• Consensus Rating: Moderate Buy

Odyssey Therapeutics Stock Analysis - MarketRank™

Odyssey Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 311th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Odyssey Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Odyssey Therapeutics has a consensus price target of $35.75, representing about 57.9% upside from its current price of $22.64.

Amount of Analyst Coverage

Odyssey Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Odyssey Therapeutics are expected to grow in the coming year, from ($5.99) to ($4.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Odyssey Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Odyssey Therapeutics is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.60% of the float of Odyssey Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Odyssey Therapeutics has a short interest ratio ("days to cover") of 10.78, which indicates bearish sentiment.

Change versus previous month

Short interest in Odyssey Therapeutics has recently decreased by 0.01%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Odyssey Therapeutics does not currently pay a dividend.

Dividend Growth

Odyssey Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.81

News Sentiment

Odyssey Therapeutics has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Odyssey Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for ODTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Odyssey Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Odyssey Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ODTX
• CIK: 1882782
• Web: odysseytx.com
• Phone: 617-865-9628
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Odyssey Therapeutics: $35.75
• High Price Target: $44.00
• Low Price Target: $29.00
• Potential Upside/Downside: +57.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.36
• Quick Ratio: 11.36

Sales & Book Value

• Annual Sales: $99 thousand
• Price / Sales: 10,990.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 48,059,000
• Free Float: N/A
• Market Cap: $1.09 billion
• Optionable: N/A
• Beta: N/A